What is Strontium Ranelate?
Strontium ranelate is a pharmaceutical compound that combines strontium, a mineral chemically similar to calcium, with ranelic acid. While strontium occurs naturally as a trace element in the human body and environment, strontium ranelate is a synthetic medication specifically developed for treating osteoporosis. Originally approved in Europe for postmenopausal osteoporosis and osteoporosis in men at high fracture risk, its availability has become restricted due to cardiovascular safety concerns. The compound is not currently approved by the FDA in the United States and is not available as a dietary supplement.
Strontium ranelate differs significantly from other strontium compounds like strontium citrate or strontium chloride that may be found in some supplements. The ranelic acid component is crucial for the medication’s specific therapeutic effects and safety profile. Understanding this distinction is important, as the clinical research on bone health primarily involves strontium ranelate rather than other strontium forms.
Health benefits & uses
Osteoporosis treatment (Strong evidence): Multiple large-scale clinical trials have demonstrated strontium ranelate’s effectiveness in reducing vertebral and hip fractures in postmenopausal women with osteoporosis. The SOTI and TROPOS trials showed significant reductions in fracture risk, with vertebral fracture risk reduced by approximately 40% and hip fracture risk reduced by 16% over three years of treatment.
Bone mineral density improvement (Strong evidence): Clinical studies consistently show that strontium ranelate increases bone mineral density at both spine and hip sites. The increases are typically greater than those seen with other osteoporosis medications, though this is partly due to strontium’s higher atomic weight compared to calcium, which can artificially elevate bone density measurements.
Male osteoporosis (Moderate evidence): Research has shown strontium ranelate can reduce vertebral fracture risk in men with osteoporosis, though the evidence base is smaller than for postmenopausal women. Studies demonstrate improved bone mineral density and reduced fracture incidence in older men at high fracture risk.
How it works
Strontium ranelate exhibits a unique dual mechanism of action on bone tissue, simultaneously promoting bone formation while reducing bone resorption. The compound stimulates osteoblast activity and proliferation, the cells responsible for building new bone tissue. Concurrently, it inhibits osteoclast differentiation and activity, reducing the rate of bone breakdown.
At the cellular level, strontium ranelate activates the calcium-sensing receptor on osteoblasts, triggering signaling pathways that promote bone formation. It also influences the RANK/RANKL/OPG system, a key regulatory pathway for bone remodeling, shifting the balance toward bone formation. Additionally, strontium can partially substitute for calcium in the bone mineral matrix, though the clinical significance of this replacement remains under investigation.
Dosage
The standard pharmaceutical dosage of strontium ranelate is 2 grams daily, typically taken as one sachet of powder dissolved in water. This medication must be prescribed by a healthcare provider and is taken on an empty stomach, preferably at bedtime, at least two hours after eating. Food, calcium supplements, and dairy products can significantly reduce absorption and should be avoided around dosing time.
No recommended dietary allowance (RDA) or upper limit (UL) exists for strontium ranelate, as it is a prescription medication rather than a nutritional supplement. Treatment duration and monitoring requirements should be determined by healthcare providers, particularly given the cardiovascular safety considerations that have emerged with long-term use.
Food sources
Strontium ranelate is not found in food sources, as it is a synthetic pharmaceutical compound. Natural strontium occurs in small amounts in various foods, including seafood, whole grains, root vegetables, and leafy greens, but these contain different forms of strontium that have not been extensively studied for bone health benefits.
The ranelic acid component of strontium ranelate is synthetic and not present in natural sources. Individuals interested in bone health should focus on established nutrients like calcium, vitamin D, magnesium, and vitamin K, which are abundantly available in foods and have well-documented safety profiles.
Safety & side effects
Strontium ranelate carries significant safety warnings, particularly regarding cardiovascular risks. The European Medicines Agency has restricted its use due to increased risks of heart attack and blood clots. Common side effects include nausea, diarrhea, headache, and skin reactions. Rare but serious adverse effects include severe skin reactions (DRESS syndrome) and venous thromboembolism.
The medication requires regular monitoring of cardiovascular risk factors, kidney function, and liver enzymes. Treatment should be discontinued if patients develop cardiovascular disease or significant risk factors. Additionally, some patients may experience temporary increases in creatine kinase levels, requiring monitoring for muscle-related side effects.
Interactions
Strontium ranelate has several important interactions that affect absorption and efficacy. Calcium supplements, dairy products, and antacids significantly reduce strontium ranelate absorption and should be separated by at least two hours. Tetracycline and quinolone antibiotics can form complexes with strontium, reducing antibiotic effectiveness.
Aluminum hydroxide-containing antacids should be avoided during treatment. Vitamin D supplements are often recommended alongside strontium ranelate to ensure adequate calcium absorption and bone metabolism, but timing of administration should be carefully managed to avoid interference.
Who should be cautious
Strontium ranelate is contraindicated in patients with current or previous cardiovascular disease, including heart attack, stroke, or peripheral artery disease. Individuals with uncontrolled hypertension, history of blood clots, or significant cardiovascular risk factors should avoid this medication. Patients with severe kidney disease or liver impairment require careful evaluation before treatment.
Pregnant and breastfeeding women should not use strontium ranelate, as safety data is lacking. Patients with phenylketonuria should be aware that some formulations contain aspartame. Regular cardiovascular risk assessment is essential for all patients considering this treatment.
Frequently asked questions
Is strontium ranelate the same as strontium supplements?
No, strontium ranelate is a specific pharmaceutical compound combining strontium with ranelic acid. It differs significantly from strontium citrate or other forms found in dietary supplements, which have not undergone the same rigorous clinical testing for bone health or safety evaluation.
Why was strontium ranelate restricted in Europe?
European regulators restricted strontium ranelate due to increased cardiovascular risks, including heart attacks and blood clots. The medication is now only available for patients with severe osteoporosis who cannot use other treatments and have low cardiovascular risk.
Can I take strontium ranelate with calcium supplements?
Calcium supplements significantly interfere with strontium ranelate absorption and should be separated by at least two hours. Many healthcare providers recommend taking strontium ranelate at bedtime and calcium supplements earlier in the day to minimize interaction.
How long does strontium ranelate treatment typically last?
Treatment duration varies based on individual circumstances and cardiovascular risk assessment. Given the safety concerns, healthcare providers regularly evaluate the benefit-risk ratio and may recommend shorter treatment courses than previously prescribed.
Are there alternatives to strontium ranelate for osteoporosis?
Yes, several alternative osteoporosis treatments exist, including bisphosphonates, denosumab, teriparatide, and hormone therapy. These alternatives often have different safety profiles and may be more appropriate depending on individual patient characteristics and risk factors.
Classification:
Typical dose: — · Studied up to: —
References
Authoritative profile & live regulatory status: Strontium Ranelate on SupplementIndex →